ADAMTS13 and TTP.

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Thrombotic thrombocytopenic purpura (TTP) is a severe, often fatal, thrombotic microangiopathy.
• Historically, TTP treatment relied on plasma exchange without a clear understanding of its pathophysiology.
• Recent research implicates von Willebrand factor (VWF) processing in TTP pathogenesis.

Purpose of the Study:

• To elucidate the underlying molecular mechanisms of TTP.
• To identify the specific protease responsible for VWF multimer cleavage.
• To explore the role of this protease in TTP development and its potential as a diagnostic and therapeutic target.

Main Methods:

• Investigated the role of VWF multimers in platelet thrombus formation.
• Identified a specific VWF cleaving protease.
• Characterized the protease as a member of the ADAMTS family, designated ADAMTS13.
• Examined the association of autoantibodies against ADAMTS13 with sporadic TTP.
• Studied mutations in the ADAMTS13 gene in familial TTP.

Main Results:

• Deficiency of the VWF cleaving protease, ADAMTS13, promotes microvascular thrombosis in TTP.
• ADAMTS13 is responsible for the proteolytic cleavage of VWF multimers, regulating platelet thrombus growth.
• Autoantibodies inhibiting ADAMTS13 activity cause sporadic TTP.
• Mutations in the ADAMTS13 gene lead to an autosomal recessive form of chronic relapsing TTP.

Conclusions:

• ADAMTS13 deficiency is central to the pathophysiology of TTP.
• Understanding ADAMTS13 is crucial for diagnosing and treating TTP.
• Targeting ADAMTS13 holds promise for future therapeutic strategies in TTP and other thrombotic microangiopathies.